Fever and respiratory tract symptoms were highlighted early in the COVID-19 outbreak and are widely considered to be the main symptoms of COVID-19. As the outbreak has evolved, GI tract complaints (notably vomiting, diarrhea, anorexia, and abdominal pain) have emerged as prevalent symptoms, which sometimes occur in the absence of non-GI tract symptoms. Compared with SARS coronavirus (SARS-CoV) 1 or MERS coronavirus, in which GI tract symptoms occurred in approximately one-quarter of infected patients,
1 Xie M. Chen Q. Insight into 2019 novel coronavirus - an updated interim review and lessons from SARS-CoV and MERS-CoV.
Int J Infect Dis. 2020; 94 : 119-124 Abstract Full Text Full Text PDF PubMed Scopus (72) Google Scholar
rates of GI tract symptoms may be lower for SARS-CoV-2, though prevalence data is still evolving and highly variable. Recent analyses describing the pooled prevalence of GI tract symptoms are summarized in Table 1. Combined results of these meta-analyses suggest that the “true” population rate of GI tract symptoms in patients with COVID-19 is likely between 10% and 20%. Table 1 Pooled Prevalence of GI Tract Symptoms From COVID-19 Meta-analyses Variable Parasa et al
4 Parasa S. Desai M. Thoguluva Chandrasekar V. et al. Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: a systematic review and meta-analysis.
JAMA Netw Open. 2020; 3 : e2011335 Crossref PubMed Scopus (20) Google Scholar
Cheung et al
5 Cheung K.S. Hung I.F.N. Chan P.P. et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis.
Gastroenterology. 2020; 159 : 81-95 Abstract Full Text Full Text PDF PubMed Google Scholar
Tariq et al
6 Tariq R. Saha S. Furqan F. Hassett L. Pardi D. Khanna S. Prevalence and mortality of COVID-19 patients with gastrointestinal symptoms: a systematic review and meta-analysis.
Mayo Clin Proc. 2020; 95 : 1632-1648 Abstract Full Text Full Text PDF PubMed Scopus (1) Google Scholar
Mao et al
7 Mao R. Qiu Y. He J.S. et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis [published correction appears in
Lancet Gastroenterol Hepatol. 2020;5(7):e6].
Lancet Gastroenterol Hepatol. 2020; 5 : 667-678 Abstract Full Text Full Text PDF PubMed Scopus (84) Google Scholar
No. of studies 29 60 78 35 No. of patients 4805 4243 12,797 6686 All GI tract symptoms NA 18% NA 15% Diarrhea 7% 13% 12% 9% Nausea/vomiting 5% 10% (vomiting) 9% 6% Abdominal pain NA 9% 6% 3% Liver injury 20% AST, 15% ALT NA NA 3% Anorexia NA 27% 22% 21% Stool sample positivity 41% 48.1% NA 54% ALT = alanine aminotransferase; AST = aspartate aminotransferase; COVID = coronavirus disease 2019; GI = gastrointestinal. Open table in a new tab